On 25 September 2026 the US FDA recorded a supplement to new drug application 207924 for baricitinib, marketed by Eli Lilly as Olumiant. The public record names the application and holder but not what the supplement changed; supplements to an innovator licence can concern labelling, manufacturing or other updates.
The record does not establish a new indication or a safety communication, so prescribing does not change on it. Readers should check the updated label directly before drawing conclusions. Baricitinib is available in India; CDSCO's position on any related change is not stated.
- No change to baricitinib prescribing follows from this notice alone.
- Check the FDA label for the specific change before counselling patients.
- Continue standard JAK inhibitor safety screening and monitoring.
- Report suspected adverse events through the national pharmacovigilance programme.
Why it matters
Licence supplements are often misread as new approvals or warnings.
Don't overread it
A licence supplement is not, by itself, a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free